|
2011 Conference Publication Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P., Lea, Rod, Mollee, Peter, Gill, Devinder S. and Gandhi, Maher K. (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, CA United States, 10-13 December 2011. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585 |
|
2011 Conference Publication Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patientsKeane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press. |
|
2011 Conference Publication Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2011 Conference Publication Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCLGandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2010 Conference Publication Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated PatientsGandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti. |
|
2008 Conference Publication Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) populationKeane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014 |
|
2006 Conference Publication Thalidomide and dexamethasone in newly diagnosed multiple myelomaMcHugh, Johnny, O'Ceallaigh, Cathal, Keane, Colm, Otridge, Brian W. and O'Gorman, Peter (2006). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 48th Annual Meeting of the American Society of Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V108.11.5120.5120 |
|
2005 Conference Publication Thalidomide and dexamethasone in newly diagnosed multiple myelomaMcHugh, Johnny, Keane, Colm, Otridge, Brian W., Thornton, Patrick and O'Gorman, Peter (2005). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.5185.5185 |
|
2004 Conference Publication Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimenMills, AK, Gibbs, S, Keane, C, Mollee, P, Grimmett, K, Van Kuilenburg, R, Saal, R, Gill, D, Prince, HM, Seymour, JF and Marlton, P (2004). Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen. 46th Annual Meeting of the American-Society-of-Hematology, San Diego Ca, Dec 04-07, 2004. WASHINGTON: AMER SOC HEMATOLOGY. |
